Lixin Pharmaceutical was approved by U.S. Food and Drug Administration (FDA) in 2010, and had a review with zero defect in 2015.
Lixin Pharmaceutical was approved by European Directorate for the Quality of Medicines (EDQM), European Medicines Agency (EMA) in Oct, 2016.
A number of products receive certificates of GMP by China Food and Drug Administration (NMPA)
GMP Products Clopidogrel Sulfate Idebenone Hydrochlorothiazine Indapamide Dacarbazine Ritodrine Hydrochloride Fasudil Hydrochloride Oxaliplatin
CEP Products Hydrochlorothiazine Indapamide Dacarbazine
GMP Products Nilotinib Hydrochloride Pemetrexed Disodium Hydrochlorothiazine Clopidogrel Sulfate Idebenone Bortezomib Gefitinib Temozolomide Ticagrelor Indapamide
Pemetrexed Disodium Tenofovir Disoproxil Fumarate Capecitabine Bortezomib Gefitinib Erlotinib Hydrochloride Ticagrelor Temozolomide
Lixin Pharmaceutical has built a highly qualified R&D team and has built completely furnished professional laboratories and workshops. We can provide full range of services to clients both domestic and oversea, including R&D, quality research, registration, and customized production etc.